NCT03583853

Brief Summary

Systemic lupus erythematosus is systemic autoimmune disease characterized by a wide range of clinical manifestations, from skin and mucosal lesions to severe injuries in the central nervous system, kidneys and other organs. The presence of high titres of autoantibodies against nuclear components, immune complexes deposition, complement deficiency and lymphocytes infiltration in affected tissues, which causes tissue and organ damage are the main characteristics of the disease. Nowadays, many studies elucidate the essential role of autophagy in the occurrence, development and severity of systemic lupus erythematosus.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jul 2019

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 22, 2018

Completed
20 days until next milestone

First Posted

Study publicly available on registry

July 12, 2018

Completed
12 months until next milestone

Study Start

First participant enrolled

July 1, 2019

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2020

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2020

Completed
Last Updated

July 12, 2018

Status Verified

July 1, 2018

Enrollment Period

1 year

First QC Date

June 22, 2018

Last Update Submit

July 11, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in the expression of autophagy genes in systemic lupus erythematosus patients group and control group

    the expression of autophagy genes will be measured by real time polymerase chain reaction

    Baseline and 6 months

Study Arms (2)

patients

take 5 ml blood for isolation of peripheral blood mono-nuclear cells then extraction of Ribonucleic acid (RNA) to determine the expression of autophagy genes by real time polymerase chain reaction (real time PCR)

Device: real time PCR

control

take 5 ml blood for isolation of peripheral blood mono-nuclear cells then extraction of RNA to determine the expression of autophagy genes real time polymerase chain reaction

Device: real time PCR

Interventions

real time PCR will be used for determination of expression of autophagy genes

controlpatients

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

SLE patients are evaluated according to the SLE disease activity index 2000 (SLEDAI) and classified into two groups, one having active disease and the other group with inactive disease

You may qualify if:

  • patients who fulfilled at least four criteria of systemic lupus erythematosus according to American College of Rheumatology

You may not qualify if:

  • Pregnancy or lactation.
  • coexistence of other autoimmune diseases.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (10)

  • Ciccacci C, Perricone C, Alessandri C, Latini A, Politi C, Delunardo F, Pierdominici M, Conti F, Novelli G, Ortona E, Borgiani P. Evaluation of ATG5 polymorphisms in Italian patients with systemic lupus erythematosus: contribution to disease susceptibility and clinical phenotypes. Lupus. 2018 Aug;27(9):1464-1469. doi: 10.1177/0961203318776108. Epub 2018 May 14.

    PMID: 29759048BACKGROUND
  • Klionsky DJ. Autophagy: from phenomenology to molecular understanding in less than a decade. Nat Rev Mol Cell Biol. 2007 Nov;8(11):931-7. doi: 10.1038/nrm2245.

    PMID: 17712358BACKGROUND
  • Zhang Y, Morgan MJ, Chen K, Choksi S, Liu ZG. Induction of autophagy is essential for monocyte-macrophage differentiation. Blood. 2012 Mar 22;119(12):2895-905. doi: 10.1182/blood-2011-08-372383. Epub 2012 Jan 5.

    PMID: 22223827BACKGROUND
  • Dang J, Li J, Xin Q, Shan S, Bian X, Yuan Q, Liu N, Ma X, Li Y, Liu Q. Gene-gene interaction of ATG5, ATG7, BLK and BANK1 in systemic lupus erythematosus. Int J Rheum Dis. 2016 Dec;19(12):1284-1293. doi: 10.1111/1756-185X.12768. Epub 2015 Sep 30.

    PMID: 26420661BACKGROUND
  • Zhu L, Wang H, Wu Y, He Z, Qin Y, Shen Q. The Autophagy Level Is Increased in the Synovial Tissues of Patients with Active Rheumatoid Arthritis and Is Correlated with Disease Severity. Mediators Inflamm. 2017;2017:7623145. doi: 10.1155/2017/7623145. Epub 2017 Feb 1.

    PMID: 28255205BACKGROUND
  • Teruel M, Alarcon-Riquelme ME. The genetic basis of systemic lupus erythematosus: What are the risk factors and what have we learned. J Autoimmun. 2016 Nov;74:161-175. doi: 10.1016/j.jaut.2016.08.001. Epub 2016 Aug 10.

    PMID: 27522116BACKGROUND
  • Zhou XJ, Lu XL, Lv JC, Yang HZ, Qin LX, Zhao MH, Su Y, Li ZG, Zhang H. Genetic association of PRDM1-ATG5 intergenic region and autophagy with systemic lupus erythematosus in a Chinese population. Ann Rheum Dis. 2011 Jul;70(7):1330-7. doi: 10.1136/ard.2010.140111.

    PMID: 21622776BACKGROUND
  • Godsell J, Rudloff I, Kandane-Rathnayake R, Hoi A, Nold MF, Morand EF, Harris J. Clinical associations of IL-10 and IL-37 in systemic lupus erythematosus. Sci Rep. 2016 Oct 6;6:34604. doi: 10.1038/srep34604.

    PMID: 27708376BACKGROUND
  • Lopez P, Alonso-Perez E, Rodriguez-Carrio J, Suarez A. Influence of Atg5 mutation in SLE depends on functional IL-10 genotype. PLoS One. 2013 Oct 18;8(10):e78756. doi: 10.1371/journal.pone.0078756. eCollection 2013.

    PMID: 24205307BACKGROUND
  • Ward MM, Marx AS, Barry NN. Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus. J Rheumatol. 2000 Mar;27(3):664-70.

    PMID: 10743805BACKGROUND

MeSH Terms

Conditions

Lupus Erythematosus, Systemic

Interventions

Real-Time Polymerase Chain Reaction

Condition Hierarchy (Ancestors)

Connective Tissue DiseasesSkin and Connective Tissue DiseasesAutoimmune DiseasesImmune System Diseases

Intervention Hierarchy (Ancestors)

Polymerase Chain ReactionNucleic Acid Amplification TechniquesGenetic TechniquesInvestigative Techniques

Central Study Contacts

Mohamed Ali el-feky, prof

CONTACT

Mohamed Saad Badary, prof

CONTACT

Study Design

Study Type
observational
Observational Model
CASE CROSSOVER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
principle investigator

Study Record Dates

First Submitted

June 22, 2018

First Posted

July 12, 2018

Study Start

July 1, 2019

Primary Completion

July 1, 2020

Study Completion

December 1, 2020

Last Updated

July 12, 2018

Record last verified: 2018-07